Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
申请公布号
WO2014055667(A1)
申请公布日期
2014.04.10
申请号
WO2013US63096
申请日期
2013.10.02
申请人
SILVERGATE PHARMACEUTICALS, INC.;UNIVERSITY OF KANSAS
